RELIEF THERAPEUTICS HLDG - RLFTF STOCK NEWS

Relief Therapeutics has reported positive trial results for its drug aviptadil in treating critical COVID-19 patients with respiratory failure. In a study published in the Journal of Infectious Diseases and Treatment, aviptadil demonstrated a 60-day survival rate of 81%, significantly higher than the 21% survival rate of standard care (P<.0001). Additionally, the treatment showed a 9-fold advantage in recovery from respiratory failure (P<.0001). These results further support Relief's ongoing clinical programs and partnerships aimed at addressing high unmet medical needs.

Relief Therapeutics announced that its U.S. partner, NRx Pharmaceuticals, has submitted a revised Investigational New Drug module for ZYESAMI (aviptadil) to the FDA, confirming Nephron Pharmaceuticals can supply the drug commercially. Additionally, NRx received positive audit results from a European QP Auditor at a separate facility. Relief's lead candidate, RLF-100 (aviptadil), targets respiratory deficiency due to COVID-19 and has undergone late-stage clinical testing.

Relief Therapeutics reported positive safety findings for ZYESAMI (RLF-100) in the NIH-sponsored ACTIV-3b study. The Independent Data Safety Monitoring Board reviewed data from 231 patients and confirmed no new safety concerns, recommending continued patient enrollment. The company emphasizes its commitment to addressing unmet medical needs with innovative therapies while also strengthening its pipeline through collaborations and acquisitions. The progress of RLF-100, particularly in treating respiratory issues related to COVID-19, remains a focus for Relief.

Relief Therapeutics announces that its subsidiary, APR Applied Pharma Research, published findings in the Journal of Wound Care indicating that Nexodyn(R) Acid-Oxidizing Solution (AOS) exhibits superior wound healing compared to standard care. Conducted by experts in Austria, the study involved 50 patients and demonstrated significant improvements including a healing rate of 32% with Nexodyn(R) versus 8% with standard treatment. The study confirmed Nexodyn(R)'s safety, tolerability, and its ability to reduce wound pH, promoting faster healing.

Relief Therapeutics Holding SA (OTCQB: RLFTF) announced that its U.S. partner, NRx Pharmaceuticals, has reported positive top-line data for ZYESAMI™ (RLF-100™/aviptadil) in highly comorbid COVID-19 patients. The treatment showed a threefold increase in one-year survival rates, consistent with prior phase 2b/3 trial results indicating enhanced 60-day survival rates. Relief focuses on clinical-stage therapies, with RLF-100™ targeting respiratory deficiencies due to COVID-19. The company also diversifies its pipeline through collaborations and recent acquisitions.

Relief Therapeutics Holding SA reported its half-year results for 2021, highlighting a focus on developing therapeutic products for severe diseases. The company has transformed into a multi-product, revenue-generating entity, primarily driven by the acquisition of APR Applied Pharma Research. Key developments include the filing of an NDA for ACER-001 and ongoing trials for RLF-100 (aviptadil), aimed at treating COVID-19 and other serious conditions. Despite a net loss of CHF 14.7 million, Relief maintains a strong cash position of CHF 40 million, positioning itself for strategic growth.

Relief Therapeutics announced positive findings regarding its PKU GOLIKE(R) product, developed by its subsidiary APR Applied Pharma Research. Data published in Nutrients suggests that the controlled release amino acid mix can reduce catabolic events in patients with phenylketonuria (PKU), enhancing amino acid utilization and improving quality of life. The product is recognized for its prolonged-release formulation which mimics natural protein absorption. Future clinical assessments are planned to support these findings, aiming for PKU GOLIKE(R) to become a prescription product in the U.S.

Relief Therapeutics announced on September 13, 2021, that it received scientific advice from the MHRA regarding its lead drug candidate, RLF-100 (aviptadil), aimed at treating respiratory deficiency in severe COVID-19 cases. The MHRA suggested a conditional marketing approval (CMA) pathway, allowing for early access to treatments. Relief also discussed the regulatory path with the EMA and indicated ongoing dialogue with the MHRA for necessary data from a Phase 2b/3 study conducted by NeuroRx. However, NeuroRx has yet to provide all required data, presenting potential risks.

Relief Therapeutics has announced the launch of PKU GOLIKE(R) KRUNCH, a chewable tablet designed for the dietary management of phenylketonuria (PKU), a rare genetic disorder affecting around 350,000 individuals globally. This new product aims to enhance patient adherence to therapy, providing a convenient 'on-the-go' option. The launch, taking place in Germany and Italy, leverages the Physiomimic Technology(TM) to offer a prolonged-release formulation that masks the product's unpleasant taste. Future expansion plans include additional markets across Europe.